Editas Medicine Inc (EDIT)
5.50
-0.54
(-8.94%)
USD |
NASDAQ |
Jun 13, 16:00
5.50
0.00 (0.00%)
After-Hours: 16:29
Editas Medicine Revenue (TTM): 69.41M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 69.41M |
December 31, 2023 | 78.12M |
September 30, 2023 | 24.61M |
June 30, 2023 | 19.32M |
March 31, 2023 | 22.79M |
December 31, 2022 | 19.71M |
September 30, 2022 | 25.64M |
June 30, 2022 | 31.80M |
March 31, 2022 | 25.82M |
December 31, 2021 | 25.54M |
September 30, 2021 | 24.49M |
June 30, 2021 | 81.14M |
March 31, 2021 | 91.51M |
December 31, 2020 | 90.73M |
September 30, 2020 | 91.60M |
June 30, 2020 | 32.60M |
March 31, 2020 | 24.18M |
Date | Value |
---|---|
December 31, 2019 | 20.53M |
September 30, 2019 | 14.37M |
June 30, 2019 | 25.04M |
March 31, 2019 | 30.08M |
December 31, 2018 | 31.94M |
September 30, 2018 | 29.48M |
June 30, 2018 | 21.25M |
March 31, 2018 | 16.97M |
December 31, 2017 | 13.73M |
September 30, 2017 | 10.96M |
June 30, 2017 | 5.639M |
March 31, 2017 | 5.93M |
December 31, 2016 | 6.053M |
September 30, 2016 | 5.947M |
June 30, 2016 | 5.655M |
March 31, 2016 | 2.434M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
14.37M
Minimum
Sep 2019
91.60M
Maximum
Sep 2020
41.95M
Average
25.59M
Median
Revenue (TTM) Benchmarks
Vertex Pharmaceuticals Inc | 10.18B |
Bristol-Myers Squibb Co | 45.53B |
Regeneron Pharmaceuticals Inc | 13.10B |
Cabaletta Bio Inc | -- |
Oragenics Inc | -- |